➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Dow
McKinsey
AstraZeneca
Medtronic

Last Updated: November 27, 2020

DrugPatentWatch Database Preview

Claims for Patent: 7,410,656

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,410,656
Title:Anti-cancer compounds
Abstract: This invention relates to a compound or group of compounds present in an active principle derived from plants of species Euphorbia peplus, Euphorbia hirta and Euphorbia drummondii, and to pharmaceutical compositions comprising these compounds. Extracts from these plants have been found to show selective cytotoxicity against several different cancer cell lines. The compounds are useful in effective treatment of cancers, particularly malignant melanomas and squamous cell carcinomas (SCCs). In a preferred embodiment of the invention, the compound is selected from the group consisting of jatrophanes, pepluanes, paralianes and ingenanes, and pharmaceutically-acceptable salts or esters thereof, and more particularly jatrophanes of Conformation II.
Inventor(s): Aylward; James Harrison (St. Lucia, AU)
Assignee: Peplin Research Pty. Ltd. (Fortitude Valley, AU)
Application Number:10/896,811
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,410,656
Patent Claims: 1. A method for inhibiting proliferative activity of neoplastic cells in a subject, said method comprising administering to a subject in need thereof a therapeutically effective amount of an isolated compound, said compound being an angeloyl-substituted ingenane.

2. The method of claim 1, wherein the compound is selected from the group consisting of an angeloyl-substituted ingenane with an acylated substitution on or at the C-20 position.

3. The method of claim 1, wherein the compound is 20-O-acetyl-ingenol-3-angelate.

4. The method of claim 1 wherein the neoplastic cells are present in a subject with cancer or a tumor.

5. The method of claim 4 wherein the cancer or tumor is selected from the group consisting of skin cancer, malignant melanoma, merkel cell carcinoma, squamous cell carcinoma, basal cell carcinoma and solar keratosis.

6. The method of claim 4 wherein the cancer or tumor is selected from the group consisting of a solid tumor, lung cancer, colon cancer, prostate cancer, cervical cancer and breast cancer.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Dow
Moodys
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.